2017 Fiscal Year Final Research Report
Umbilical cord extracts improve diabetic abnormalities in bone marrow-derived mesenchymal stem cells and increase their therapeutic effects on diabetic nephropathy
| Project/Area Number |
26460279
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General anatomy (including histology/embryology)
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
藤宮 峯子 札幌医科大学, 医学部, 教授 (10199359)
有村 佳昭 札幌医科大学, 医学部, 研究員 (80305218)
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Keywords | 間葉系幹細胞 / 糖尿病性腎症 |
|---|
| Outline of Final Research Achievements |
Bone marrow-derived mesenchymal stem cells (BM-MSC) has been applied as the most valuable source of autologous cell transplantation for diabetic complications. However, hyperglycemia may cause abnormalities in intrinsic BM-MSC which might lose sufficient therapeutic effects in diabetic patients. We demonstrated the functional abnormalities in BM-MSC derived from diabetes models (DM-MSC) in vitro, which resulted in loss of therapeutic effects in vivo in diabetic nephropathy (DN). Then, we developed a novel method to improve abnormalities in BM-MSC using human umbilical cord extracts, namely Wharton’s jelly extract supernatant (WJs). WJs ameliorated proliferative capacity, motility, mitochondrial degeneration, endoplasmic reticular functions in DM-MSC. DM-MSC activated by WJs ameliorated renal injury in DN. In this study, we developed a novel activating method using WJs to significantly increase the therapeutic effect of BM-MSC, which may allow effective autologous cell transplantation.
|
| Free Research Field |
再生医療、糖尿病
|
